Needham & Company Downgrades Gilead Sciences (GILD) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Jefferies Remains Sidelined on Gilead Sciences (GILD) Following 2Q - PT to $93
July 26, 2016 9:15 AM EDTJefferies maintained a Hold rating on Gilead Sciences (NASDAQ: GILD), and cut the price target to $93.00 (from $97.00) following the company's 2Q earnings report. GILD's strong bottom-line results were driven by HIVB strength, as well as buybacks. HIV sales remain strong, with particular... More
Gilead Sciences (GILD) PT Bumped to $98 at BMO Capital Posts Q2, Remains Sidelined
July 26, 2016 8:26 AM EDTBMO Capital analyst Ian Somaiya bumped his price target on Gilead Sciences (NASDAQ: GILD) to $98.00 (from $97.00) but maintained a Market Perform rating following Q2 results after the close.
Somaiya commented, "Gilead's 2Q16 results support our below-consensus view of the company's HCV... More
Gilead Sciences (GILD) PT Lowered to $108 at Piper Jaffray
July 26, 2016 8:10 AM EDTPiper Jaffray analyst Joshua Schimmer lowered his price target on Gilead Sciences (NASDAQ: GILD) to $108.00 (from $114.00) following results and lowered guidance but maintained an Overweight rating.
Schimmer commented, "After the close, GILD reported 2Q results, lowering its revenue and raising its opex guidance... More
Gilead Sciences (GILD) PT Trimmed to $115 at Credit Suisse
July 26, 2016 7:53 AM EDTCredit Suisse analyst Alethia Young lowered estimates and her price target on Gilead Sciences (NASDAQ: GILD) to $115.00 (from $120.00) following results but maintained a Outperform rating.
Young commented, "Harvoni was the focus heading into the quarter; it missed consensus and guidance was lowered (likely due to HCV). Total revenues... More
Gilead Sciences (GILD): Lower Revenue Guidance Highlights Concerns - Baird
July 26, 2016 6:16 AM EDTBaird analyst, Brian Skorney, reiterated his Outperform rating on shares of Gilead Sciences (NASDAQ: GILD) but is incrementally more cautious after earnings. Though Hep C sales met expectations, management didn't show as much confidence in a stabilization as they have in the... More
Gilead Sciences (GILD) Tops Q2 EPS by 6c
July 25, 2016 4:09 PM EDTGilead Sciences (NASDAQ: GILD) reported Q2 EPS of $3.08, $0.06 better than the analyst estimate of $3.02. Revenue for the quarter came in at $7.78 billion versus the consensus estimate of $7.79 billion.
otal product sales for the second quarter of 2016 were $7.7 billion compared to $8.1 billion for the same period in 2015. Product sales for the second quarter of 2016 were $4.9... More
